Literature DB >> 24243768

Efficacy of a sclerostin antibody compared to a low dose of PTH on metaphyseal bone healing.

Fredrik Agholme1, Brandon Macias, Matt Hamang, Jonathan Lucchesi, Mary D Adrian, Stuart Kuhstoss, Anita Harvey, Masahiko Sato, Per Aspenberg.   

Abstract

We compared the effect of a sclerostin antibody to that of a clinically relevant dose of parathyroid hormone (PTH) in a rat model for metaphyseal bone healing. Screws of steel or poly methyl methacrylate (PMMA) were inserted bilaterally into the proximal tibia of young male rats. During 4 weeks the animals then received injections of either phosphate buffered saline (control), sclerostin antibody (25 mg/kg, twice weekly) or PTH (5 µg/kg, daily). The healing response around the screws was then assessed by mechanical testing and X-ray microtomography (µCT). To distinguish between effects on healing and general effects on the skeleton, other untraumatized bone sites and serum biomarkers were also assessed. After 4 weeks of treatment, PTH yielded a 48% increase in screw pull-out force compared to control (p = 0.03), while the antibody had no significant effect. In contrast, the antibody increased femoral cortical and vertebral strength where PTH had no significant effect. µCT showed only slight changes that were statistically significant for the antibody mainly at cortical sites. The results suggest that a relatively low dose of PTH stimulates metaphyseal repair (screw fixation) specifically, whereas the sclerostin antibody has wide-spread effects, mainly on cortical bone, with less influence on metaphyseal healing.
© 2013 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.

Entities:  

Keywords:  Wnt-signaling; bone formation; bone healing; implant fixation; mechanical testing

Mesh:

Substances:

Year:  2013        PMID: 24243768     DOI: 10.1002/jor.22525

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  11 in total

1.  The effects of sclerostin antibody plus parathyroid hormone (1-34) on bone formation in ovariectomized rats.

Authors:  Jian Wu; Xian-Hua Cai; Xing-Xing Qin; Yan-Xi Liu
Journal:  Z Gerontol Geriatr       Date:  2017-03-31       Impact factor: 1.281

Review 2.  Inhibitors of sclerostin: emerging concepts.

Authors:  Matthew T Drake; Joshua N Farr
Journal:  Curr Opin Rheumatol       Date:  2014-07       Impact factor: 5.006

3.  Effect of sequential treatments with alendronate, parathyroid hormone (1-34) and raloxifene on cortical bone mass and strength in ovariectomized rats.

Authors:  Sarah K Amugongo; Wei Yao; Junjing Jia; Weiwei Dai; Yu-An E Lay; Li Jiang; Danielle Harvey; Elizabeth A Zimmermann; Eric Schaible; Neil Dave; Robert O Ritchie; Donald B Kimmel; Nancy E Lane
Journal:  Bone       Date:  2014-07-10       Impact factor: 4.398

4.  Role of Wnt/β-catenin and RANKL/OPG in bone healing of diabetic Charcot arthropathy patients.

Authors:  Agnetha Folestad; Martin Ålund; Susanne Asteberg; Jesper Fowelin; Ylva Aurell; Jan Göthlin; Jean Cassuto
Journal:  Acta Orthop       Date:  2015-03-26       Impact factor: 3.717

5.  Alendronate-eluting polyglucose-lignol composite (POGLICO): a new biomaterial for fracture fixating implants.

Authors:  Per Aspenberg
Journal:  Acta Orthop       Date:  2014-10-28       Impact factor: 3.717

6.  Experimental models for cancellous bone healing in the rat.

Authors:  Magnus Bernhardsson; Olof Sandberg; Per Aspenberg
Journal:  Acta Orthop       Date:  2015-08-27       Impact factor: 3.717

7.  Different effects of Wnt/β-catenin activation and parathyroid hormone on diaphyseal and metaphyseal in the early phase of femur bone healing of mice.

Authors:  Daocheng Liu; Sihao He; Sixu Chen; Lei Yang; Jiazhi Yang; Quanwei Bao; Hao Qin; Yufeng Zhao; Zhaowen Zong
Journal:  Clin Exp Pharmacol Physiol       Date:  2019-04-21       Impact factor: 2.557

8.  Different effects of Wnt/β-catenin activation and PTH activation in adult and aged male mice metaphyseal fracture healing.

Authors:  Daocheng Liu; Hao Qin; Jiazhi Yang; Lei Yang; Sihao He; Sixu Chen; Quanwei Bao; Yufeng Zhao; Zhaowen Zong
Journal:  BMC Musculoskelet Disord       Date:  2020-02-19       Impact factor: 2.362

Review 9.  Pathogenesis and potential relative risk factors of diabetic neuropathic osteoarthropathy.

Authors:  Hong-Mou Zhao; Jia-Yu Diao; Xiao-Jun Liang; Feng Zhang; Ding-Jun Hao
Journal:  J Orthop Surg Res       Date:  2017-10-02       Impact factor: 2.359

10.  Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: A case report.

Authors:  Masafumi Kashii; Kosuke Ebina; Kazuma Kitaguchi; Hideki Yoshikawa
Journal:  Bone Rep       Date:  2020-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.